|
1
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsuya A, Kurata T, Tamura K and Fukuoka M:
Skeletal metastases in non-small cell lung cancer: A retrospective
study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Svensson E, Christiansen CF, Ulrichsen SP,
Rørth MR and Sørensen HT: Survival after bone metastasis by primary
cancer type: A Danish population-based cohort study. BMJ Open.
7:e0160222017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rades D, Walz J, Stalpers LJA, Veninga T,
Schulte R, Obralic N, Wildfang I, Engenhart-Cabilic R, Hoskin PJ
and Schild SE: Short-course radiotherapy (RT) for metastatic spinal
cord compression (MSCC) due to renal cell carcinoma: Results of a
retrospective multi-center study. Eur Urol. 49:846–852. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chow R, Hoskin P, Schild SE, Raman S, Im
J, Zhang D, Chan S, Chiu N, Chiu L, Lam H, et al: Single vs
multiple fraction palliative radiation therapy for bone metastases:
Cumulative meta-analysis. Radiother Oncol. 141:56–61. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rades D, Lange M, Veninga T, Stalpers LJ,
Bajrovic A, Adamietz IA, Rudat V and Schild SE: Final results of a
prospective study comparing the local control of short-course and
long-course radiotherapy for metastatic spinal cord compression.
Int J Radiat Oncol Biol Phys. 79:524–530. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rades D, Segedin B, Conde-Moreno AJ,
Garcia R, Perpar A, Metz M, Badakhshi H, Schreiber A, Nitsche M,
Hipp P, et al: Radiotherapy with 4 Gy × 5 versus 3 Gy × 10 for
metastatic epidural spinal cord compression: Final results of the
SCORE-2 trial (ARO 2009/01). J Clin Oncol. 34:597–602. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Makita K, Hamamoto Y, Kanzaki H, Kataoka
M, Yamamoto S, Nagasaki K, Ishikawa H, Takata N, Tsuruoka S, Uwatsu
K and Kido T: Local control of bone metastases treated with
external beam radiotherapy in recent years: A multicenter
retrospective study. Radiat Oncol. 16:2252021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Makita K, Hamamoto Y, Kanzaki H, Nagasaki
K, Takata N, Tsuruoka S, Uwatsu K and Kido T: Factors affecting
local control of bone metastases from radioresistant tumors treated
with palliative external beam radiotherapy. Discov Oncol.
14:742023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katagiri H, Okada R, Takagi T, Takahashi
M, Murata H, Harada H, Nishimura T, Asakura H and Ogawa H: New
prognostic factors and scoring system for patients with skeletal
metastasis. Cancer Med. 3:1359–1367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bollen L, van der Linden YM, Pondaag W,
Fiocco M, Pattynama BP, Marijnen CA, Nelissen RG, Peul WC and
Dijkstra PD: Prognostic factors associated with survival in
patients with symptomatic spinal bone metastases: A retrospective
cohort study of 1,043 patients. Neuro Oncol. 16:991–998. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Westhoff PG, de Graeff A, Monninkhof EM,
Bollen L, Dijkstra SP, van der Steen-Banasik EM, van Vulpen M, Leer
JW, Marijnen CA and van der Linden YM; Dutch Bone Metastasis Study
Group, : An easy tool to predict survival in patients receiving
radiation therapy for painful bone metastases. Int J Radiat Oncol
Biol Phys. 90:739–747. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Willeumier JJ, van der Linden YM, van der
Wal CWPG, Jutte PC, van der Velden JM, Smolle MA, van der Zwaal P,
Koper P, Bakri L, de Pree I, et al: An easy-to-use prognostic model
for survival estimation for patients with symptomatic long bone
metastases. J Bone Joint Surg Am. 100:196–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Motzer RJ, Hutson TE, Tomczal P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heng DY, Xie W, Regan MM, Harshman LC,
Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan
MH, et al: External validation and comparison with other models of
the international metastatic renal-cell carcinoma database
consortium prognostic model: A population-based study. Lancet
Oncol. 14:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Makita K, Kanzaki H, Hamamoto Y, Nagasaki
K, Kataoka M, Kido T and Ohsumi S: Prognostic assessment of
patients who receive radiotherapy for bone metastases from breast
cancer. Oncol Lett. 25:1882023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Makita K, Hamamoto Y, Kanzaki H, Nagasaki
K and Kozuki T: An easy tool to predict survival in patients with
bone metastatic lung cancer treated with palliative radiotherapy.
Thorac Cancer. 14:1795–1801. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan Z, Huang Z and Huang X: Bone
metastasis in renal cell carcinoma patients: Risk and prognostic
factors and nomograms. J Oncol. 2021:55752952021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rades D, Haus R, Janssen S and Schild SE:
An easy-to-use scoring system to estimate the survival of patients
irradiated for bone metastases from lung cancer. Transl Lung Cancer
Res. 9:1067–1073. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rades D, Freundt K, Meyners T, Bajrovic A,
Basic H, Karstens JH, Adamietz IA, Wildfang I, Rudat V, Schild SE
and Dunst J: Dose escalation for metastatic spinal cord compression
in patients with relatively radioresistant tumors. Int J Radiat
Oncol Biol Phys. 80:1492–1497. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freundt K, Meyners T, Bajrovic A, Basic H,
Karstens JH, Adamietz IA, Rudat V, Schild SE, Dunst J and Rades D:
Radiotherapy for oligometastatic disease in patients with spinal
cord compression (MSCC) from relatively radioresistant tumors.
Strahlenther Onkol. 186:218–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Siva S, Louie AV, Kotecha R, Barber MN,
Ali M, Zhang Z, Guckenberger M, Kim MS, Scorsetti M, Tree AC, et
al: Stereotactic body radiotherapy for primary renal cell
carcinoma: A systematic review and practice guideline from the
international society of stereotactic radiosurgery (ISRS). Lancet
Oncol. 25:e18–e28. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amini A, Altoos B, Bourlon MT, Bedrick E,
Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET and
Karam SD: Local control rates of metastatic renal cell carcinoma
(RCC) to the bone using stereotactic body radiation therapy: Is RCC
truly radioresistant? Pract Radiat Oncol. 5:e589–e596. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Altoos B, Amini A, Yacoub M, Bourlon MT,
Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET and Karam SD:
Local control rates of metastatic renal cell carcinoma (RCC) to
thoracic, abdominal, and soft tissue lesions using stereotactic
body radiotherapy (SBRT). Radiat Oncol. 10:2182015. View Article : Google Scholar : PubMed/NCBI
|
